Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy.
about
Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.Different stages in drug development for muscle-invasive bladder cancer.Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer.A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort.Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications.Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer.
P2860
Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 February 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Her2 alterations in muscle-inv ...... pression for targeted therapy.
@en
Her2 alterations in muscle-inv ...... pression for targeted therapy.
@nl
type
label
Her2 alterations in muscle-inv ...... pression for targeted therapy.
@en
Her2 alterations in muscle-inv ...... pression for targeted therapy.
@nl
prefLabel
Her2 alterations in muscle-inv ...... pression for targeted therapy.
@en
Her2 alterations in muscle-inv ...... pression for targeted therapy.
@nl
P2093
P2860
P356
P1433
P1476
Her2 alterations in muscle-inv ...... pression for targeted therapy.
@en
P2093
Achim Fleischmann
Alexander W Wyatt
Bernhard Kiss
Christine Buerki
Colin Collins
Diana Rotzer
George N Thalmann
James Douglas
Maja Neuenschwander
P2860
P2888
P356
10.1038/SREP42713
P407
P577
2017-02-16T00:00:00Z